Granted Patent
B2
US 12,325,739 · App. 18/149,593 · Granted Jun 10, 2025
Bispecific SARS-CoV-2 antibodies and methods of use
Assignee:
Twist Bioscience Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are methods and compositions relating to improved bispecific antibodies capable of binding and neutralizing SARS-CoV-2 variants.
Claims (8)
1. A bispecific antibody or an antibody fragment thereof, comprising at least two binding domains to a spike glycoprotein or a receptor of the spike glycoprotein:
a first binding domain of the at least two binding domains comprising a first variable domain, heavy chain region (VH), wherein the first VH region comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein (i) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 1; (ii) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 2; and (iii) an amino acid sequence of CDRH3 as set forth in SEQ ID NO: 3; and
a second binding domain of the at least two binding domains comprising a first variable domain, heavy chain region (VH), wherein the first VH region comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein (i) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 4; (ii) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 5; and (iii) an amino acid sequence of CDRH3 as set forth in SEQ ID NO: 6.
2. The bispecific antibody of claim 1 , wherein the bispecific antibody is bivalent, trivalent, or tetravalent.
3. The bispecific antibody of claim 1 , wherein the bispecific antibody is bivalent.
4. The bispecific antibody of claim 1 , wherein the bispecific antibody is tetravalent.
5. The bispecific antibody of claim 1 , wherein the bispecific antibody or antibody fragment thereof comprises a KD of less than 50 nM.
6. The bispecific antibody of claim 1 , wherein the bispecific antibody or antibody fragment thereof comprises a KD of less than 25 nM.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 3, 2026
From: SATO, AARON
To: TWIST BIOSCIENCE CORPORATION
Reel/Frame 075507/0414 →
Continuity (2)
Provisional Application
63296087
· Jan 3, 2022
References Cited (345)
US 5368823A
· McGraw et al.
· 1994
[cited by applicant]
US 5474796A
· Brennan
· 1995
[cited by applicant]
US 5534507A
· Cama et al.
· 1996
[cited by applicant]
US 5677195A
· Winkler et al.
· 1997
[cited by applicant]
US 5843767A
· Beattie
· 1998
[cited by applicant]
US 6013440A
· Lipshutz et al.
· 2000
[cited by applicant]
US 6028189A
· Blanchard
· 2000
[cited by applicant]
US 6419883B1
· Blanchard
· 2002
[cited by applicant]
US 6472147B1
· Janda et al.
· 2002
[cited by applicant]
US 6492107B1
· Kauffman et al.
· 2002
[cited by applicant]
US 6893816B1
· Beattie
· 2005
[cited by applicant]
US 7163660B2
· Lehmann
· 2007
[cited by applicant]
US 7202264B2
· Ravikumar et al.
· 2007
[cited by applicant]
US 8198071B2
· Goshoo et al.
· 2012
[cited by applicant]
US 9403141B2
· Banyai et al.
· 2016
[cited by applicant]
US 9409139B2
· Banyai et al.
· 2016
[cited by applicant]
US 9555388B2
· Banyai et al.
· 2017
[cited by applicant]
US 9677067B2
· Toro et al.
· 2017
[cited by applicant]
US 9745619B2
· Rabbani et al.
· 2017
[cited by applicant]
US 9765387B2
· Rabbani et al.
· 2017
[cited by applicant]
US 9833761B2
· Banyai et al.
· 2017
[cited by applicant]
US 9839894B2
· Banyai et al.
· 2017
[cited by applicant]
US 9889423B2
· Banyai et al.
· 2018
[cited by applicant]
US 9895673B2
· Peck et al.
· 2018
[cited by applicant]
US 9981239B2
· Banyai et al.
· 2018
[cited by applicant]
US 20010018512A1
· Blanchard
· 2001
[cited by applicant]
US 20020025561A1
· Hodgson
· 2002
[cited by applicant]
US 20020094533A1
· Hess et al.
· 2002
[cited by applicant]
US 20020160536A1
· Regnier et al.
· 2002
[cited by applicant]
US 20020164824A1
· Xiao et al.
· 2002
[cited by applicant]
US 20030171325A1
· Gascoyne et al.
· 2003
[cited by applicant]
US 20060127920A1
· Church et al.
· 2006
[cited by applicant]
US 20070196834A1
· Cerrina et al.
· 2007
[cited by applicant]
US 20080085511A1
· Peck et al.
· 2008
[cited by applicant]
US 20080085514A1
· Peck et al.
· 2008
[cited by applicant]
US 20080287320A1
· Baynes et al.
· 2008
[cited by applicant]
US 20090062129A1
· McKernan et al.
· 2009
[cited by applicant]
US 20090239759A1
· Balch
· 2009
[cited by applicant]
US 20090285825A1
· Kini et al.
· 2009
[cited by applicant]
US 20100004143A1
· Shibahara
· 2010
[cited by applicant]
US 20100216648A1
· Staehler et al.
· 2010
[cited by applicant]
US 20120231968A1
· Bruhn et al.
· 2012
[cited by applicant]
US 20130017642A1
· Milgrew et al.
· 2013
[cited by applicant]
US 20130109596A1
· Peterson et al.
· 2013
[cited by applicant]
US 20140106394A1
· Ko et al.
· 2014
[cited by applicant]
US 20140178992A1
· Nakashima et al.
· 2014
[cited by applicant]
US 20150120265A1
· Amirav-Drory et al.
· 2015
[cited by applicant]
US 20150196917A1
· Kay et al.
· 2015
[cited by applicant]
US 20160251651A1
· Banyai et al.
· 2016
[cited by applicant]
US 20160333340A1
· Wu
· 2016
[cited by applicant]
US 20170159044A1
· Toro et al.
· 2017
[cited by applicant]
US 20170357752A1
· Diggans
· 2017
[cited by applicant]
US 20170362589A1
· Banyai et al.
· 2017
[cited by applicant]
US 20180104664A1
· Fernandez
· 2018
[cited by applicant]
US 20180142289A1
· Zeitoun et al.
· 2018
[cited by applicant]
US 20180264428A1
· Banyai et al.
· 2018
[cited by applicant]
US 20180282721A1
· Cox et al.
· 2018
[cited by applicant]
US 20190352635A1
· Toro et al.
· 2019
[cited by applicant]
US 20200299684A1
· Toro et al.
· 2020
[cited by applicant]
US 20210002710A1
· Gantt et al.
· 2021
[cited by applicant]
US 20210102198A1
· Cox et al.
· 2021
[cited by applicant]
US 20210115594A1
· Cox et al.
· 2021
[cited by applicant]
US 20210170356A1
· Peck et al.
· 2021
[cited by applicant]
US 20210180046A1
· Cox et al.
· 2021
[cited by applicant]
US 20210207197A1
· Gantt et al.
· 2021
[cited by applicant]
US 20210332078A1
· Wu
· 2021
[cited by applicant]
US 20210348220A1
· Zeitoun et al.
· 2021
[cited by applicant]
US 20210395344A1
· Sato et al.
· 2021
[cited by applicant]
US 20220032256A1
· Lackey et al.
· 2022
[cited by applicant]
US 20220064628A1
· Toro et al.
· 2022
[cited by applicant]
US 20220106586A1
· Nugent et al.
· 2022
[cited by applicant]
US 20220106590A1
· Arbiza et al.
· 2022
[cited by applicant]
US 20220135690A1
· Sato et al.
· 2022
[cited by applicant]
US 20220135965A1
· Gantt et al.
· 2022
[cited by applicant]
US 20220206001A1
· Sato
· 2022
[cited by applicant]
US 20220243195A1
· Nugent et al.
· 2022
[cited by applicant]
US 20220246236A1
· Amirav-Drory
· 2022
[cited by applicant]
US 20220259638A1
· Brown
· 2022
[cited by applicant]
US 20220277808A1
· Arbiza et al.
· 2022
[cited by applicant]
US 20220281989A1
· Glanville
· 2022
[cited by applicant]
US 20220307010A1
· Sato et al.
· 2022
[cited by applicant]
US 20220315971A1
· Wu et al.
· 2022
[cited by applicant]
US 20220323924A1
· Lackey et al.
· 2022
[cited by applicant]
US 20220325276A2
· Banyai et al.
· 2022
[cited by applicant]
US 20220356463A1
· Shen et al.
· 2022
[cited by applicant]
US 20220356468A1
· Sato et al.
· 2022
[cited by applicant]
US 20230192818A1
· Sato
· 2023
[cited by examiner]
CN 101277758A
· 2008
[cited by applicant]
EP 3030682A2
· 2016
[cited by applicant]
JP H07505530A
· 1995
[cited by applicant]
JP 2001518086A
· 2001
[cited by applicant]
JP 2002538790A
· 2002
[cited by applicant]
JP 2004268394A
· 2004
[cited by applicant]
JP 2006503586A
· 2006
[cited by applicant]
JP 2007314746A
· 2007
[cited by applicant]
JP 2008214343A
· 2008
[cited by applicant]
JP 2009294195A
· 2009
[cited by applicant]
JP 2012507513A
· 2012
[cited by applicant]
JP 2016527313A
· 2016
[cited by applicant]
WO WO9320242A1
· 1993
[cited by applicant]
WO WO02072791A2
· 2002
[cited by applicant]
WO WO2004039953A2
· 2004
[cited by applicant]
WO WO2005059096A2
· 2005
[cited by applicant]
WO WO2008054543A2
· 2008
[cited by applicant]
WO WO2008063135A1
· 2008
[cited by applicant]
WO WO2010053443A1
· 2010
[cited by applicant]
WO WO2011109031A1
· 2011
[cited by applicant]
WO WO2012078312A2
· 2012
[cited by applicant]
WO WO2012154201A1
· 2012
[cited by applicant]
WO WO2014021938A1
· 2014
[cited by applicant]
WO WO2015021080A2
· 2015
[cited by applicant]
WO WO2022010934A2
· 2022
[cited by applicant]
WO WO2022076326A1
· 2022
[cited by applicant]
WO WO2022086866A1
· 2022
[cited by applicant]
WO WO2022087293A1
· 2022
[cited by applicant]
WO WO2022098662A2
· 2022
[cited by applicant]
WO WO2022159620A1
· 2022
[cited by applicant]
WO WO2022178137A1
· 2022
[cited by applicant]
WO WO2022204309A1
· 2022
[cited by applicant]
WO WO2022204316A2
· 2022
[cited by applicant]
WO WO2022217004A1
· 2022
[cited by applicant]
WO WO2022235579A1
· 2022
[cited by applicant]
WO WO2022235584A1
· 2022
[cited by applicant]
WO WO2022271884A2
· 2022
[cited by applicant]
WO WO2023023183A2
· 2023
[cited by applicant]
WO WO2023023190A2
· 2023
[cited by applicant]
WO WO2023023285A2
· 2023
[cited by applicant]
WO WO2023069367A1
· 2023
[cited by applicant]
Mattioli et al. 2020. On the Challenges for the Diagnosis of SARS-CoV-2 Based on a Review of Current Methodologies. ACS Sensors 2020 5 (12), 3655-3677. DOI: 10.1021/acssensors.0c01382. p. 3658, 2nd paragraph (Year: 2020…
[cited by examiner]
Seq ID No. 9 aligned with UniProt A0A679G9E9_SARS2 accessed Dec. 28, 2023 (Year: 2023).
[cited by examiner]
Seq ID No. 8 aligned with UniProt A0A679G9E9_SARS2 accessed Dec. 28, 2023 (Year: 2023).
[cited by examiner]
Seq ID No 9 aligned with Seq ID No. 7 (Year: 2023).
[cited by examiner]
Seq ID No 8 aligned with Seq ID No. 7 (Year: 2023).
[cited by examiner]
Bracken, C.J., Lim, S.A., Solomon, P. et al. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nat Chem Biol 17, 113-121 (2021). (Year: 2021).
[cited by examiner]
Agbavwe et al.: Efficiency, Error and Yield in Light-Directed Maskless Synthesis of DNA Microarrays. Journal of Nanobiotechnology. 9(57):1-17 (2011).
[cited by applicant]
Arkles et al.: The Role of Polarity in the Structure of Silanes Employed in Surface Modification. Silanes and Other Coupling Agents. 5:51-64 (2009).
[cited by applicant]
ATDBio. Nucleic Acid Structure, Nucleic Acids Book, 9 pages, published on Jan. 22, 2005. from: http://www.atdbio.com/content/5/Nucleic-acid-structure.
[cited by applicant]
ATDBio. Solid-Phase Oligonucleotide Synthesis, Nucleic Acids Book, 20 pages, Published on Jul. 31, 2011. from: http://www.atdbio.com/content/17/Solid-phase-oligonucleotide-synthesis.
[cited by applicant]
Berg: Biochemistry. 5th ED. New York (2002) 148-149.
[cited by applicant]
Blanchard et al.: High-Density Oligonucleotide Arrays. Biosensors & Bioelectronics, 11(6/7):687-690 (1996).
[cited by applicant]
Buermans et al.: Next Generation sequencing technology: Advances and applications, Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1842:1931-1941 (2014).
[cited by applicant]
Cheng et al.: High throughput parallel synthesis of oligonucleotides with 1536 channel synthesizer. Nucleic Acids Res. 30(18):e93 (2002).
[cited by applicant]
Cleary et al.: Production of complex nucleic acid libraries using highly parallel in situ oligonucleotide synthesis. Nat Methods. 1(3):241-248 (2004).
[cited by applicant]
Cohen et al.: Human population: The next half century. Science. 302:1172-1175 (2003).
[cited by applicant]
Cruse et al.: Atlas of Immunology. Third Edition. Boca Raton:CRC Press (pp. 282-283) (2010).
[cited by applicant]
Elsik et al.: The Genome sequence of taurine cattle: A window of ruminant biology and evolution. Science. 324:522-528 (2009).
[cited by applicant]
Fodor et al.: Light-directed, spatially addressable parallel chemical synthesis. Science. 251(4995):767-773 (1991).
[cited by applicant]
Gao et al.: A method for the generation of combinatorial antibody libraries using pIX phage display. PNAS 99(20):12612-12616 (2002).
[cited by applicant]
GE Healthcare. AKTA oligopilot plus. Data File 18-114-66 ADC. 8 pages (2006).
[cited by applicant]
GE Healthcare. Robust and cost-efficient oligonucleotide synthesis. Application Note 28-4058-08 AA. 4 pages (2005).
[cited by applicant]
Gibson et al.: Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome. Science. 329(5989):52-56 (2010).
[cited by applicant]
Hasin-Brumshtein et al.: The Effects of Mismatches on DNA Capture by Hybridization. Twist WhitePaper. 6 pages (May 7, 2019).
[cited by applicant]
Hastie et al.: Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science. 374:472-478 (2021).
[cited by applicant]
Hudson: Matrix Assisted Synthetic Transformations: A Mosaic of Diverse Contributions. Journal of Combinatorial Chemistry. 1(6):403-457 (1999).
[cited by applicant]
Kong et al.: Parallel gene synthesis in a microfluidic device. Nucleic Acids Res. 35(8):e61 (2007).
[cited by applicant]
Kosuri and Church. Large-scale de novo DNA synthesis: technologies and applications. Nature Methods. 11:499-507 (2014) Available at: http://www.nature.com/nmeth/journal/v11/n5/full/nmeth.2918.html.
[cited by applicant]
Kosuri et al.: A scalable gene synthesis by selective amplification of DNA pools from high-fidelity microchips. Nature Biotechnology. 28:1295-1299 (2010).
[cited by applicant]
Kosuri et al.: A scalable gene synthesis platform using high-fidelity DNA microchips Nat.Biotechnol. 28(12):1295-1299 (2010).
[cited by applicant]
Krayden, Inc.: A Guide to Silane Solutions. Silane coupling agents. 7 pages. Published on May 31, 2005 at: http://krayden.com/pdf/xia_silane_chemistry.pdf.
[cited by applicant]
Lausted et al.: POSaM: a fast, flexible, open-source, inkjet oligonucleotide synthesizer and microarrayer. Genome Biology. 5:R58, 17 pages (2004) available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC507883/.
[cited by applicant]
Lebl et al.: Economical Parallel Oligonucleotide and Peptide Synthesizer—Pet Oligator. Int. J. Peptide Res. Ther. 13(1-2):367-376 (2007).
[cited by applicant]
Leproust et al.: Synthesis of high-quality libraries of long (150mer) oligonucleotides by a novel depurination controlled process. Nucleic Acids Research. 38(8):2522-2540 (2010).
[cited by applicant]
Lewontin and Harti, Population genetics in forensic DNA typing. Science, 254:1745-1750, 1991.
[cited by applicant]
Ma et al.: DNA synthesis, assembly and application in synthetic biology. Current Opinion in Chemical Biology. 16:260-267 (2012).
[cited by applicant]
Ma et al.: Versatile surface functionalization of cyclic olefin copolymer (COC) with sputtered SiO2 thin film for potential BioMEMS applications. Journal of Materials Chemistry. 11 pages (2009).
[cited by applicant]
Mazor et al.: Isolation of Full-Length IgG Antibodies from Combinatorial Libraries Expressed in
[cited by applicant]
McBride & Caruthers. An investigation of several deoxynucleoside phosphoramidites useful for synthesizing deoxyoligonucleotides. Tetrahedron Lett. 24:245-248 (1983).
[cited by applicant]
Mitra et al.: In situ localized amplification and contact replication of many individual DNA molecules. Nucleic Acids Res. 27(24):e34 (1999).
[cited by applicant]
Morin et al.: Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. Biotechniques. 45:81-94 (2008).
[cited by applicant]
Opposition to European Patent No. 3030682 filed Mar. 3, 2021.
[cited by applicant]
PCT/US2014/049834 International Preliminary Report on Patentability dated Feb. 18, 2016.
[cited by applicant]
PCT/US2014/049834 International Search Report and Written Opinion mailed Mar. 19, 2015.
[cited by applicant]
PCT/US2014/049834 Invitation to Pay Additional Fees mailed Jan. 5, 2015.
[cited by applicant]
Pirrung. How to make a DNA chip. Angew. Chem. Int. Ed. 41:1276-1289 (2002).
[cited by applicant]
Pray. Discovery of DNA Structure and Function: Watson and Crick. Nature Education.6 pages (2008) available at: http://www.nature.com/scitable/topicpage/discovery-of-dna-structure-and-function-watson-397.
[cited by applicant]
Quan et al.: Parallel on-chip gene synthesis and application to optimization of protein expression. Nature Biotechnology. 29:449-452 (2011).
[cited by applicant]
Rafalski and Morgante. Corn and humans: recombination and linkage disequilibrium in two genomes of similar size. Trends in Genetics. 20(2):103-111 (2004).
[cited by applicant]
Rogozin et al.: Origin and evolution of spliceosomal introns. Biology Direct, 7:11 (2012).
[cited by applicant]
Saaem et al.: In situ synthesis of DNA microarray on functionalized cyclic olefin copolymer substrate ACS Applied Materials & Interfaces. 2(2):491-497 (2010).
[cited by applicant]
Sargolzaei et al.: Extent of linkage disequilibrium in Holstein cattle in North America. J.Dairy Science. 91:2106-2117 (2007).
[cited by applicant]
Srivannavit et al.: Design and fabrication of microwell array chips for a solution-based, photogenerated acid-catalyzed parallel oligonucleotide DNA synthesis. Sensors and Actuators A. 116:150-160 (2004).
[cited by applicant]
STEEL. The Flow-Thru Chip a Three-dimensional biochip platform. In: Schena, Microarray Biochip Technology, Chapter 5, Natick, MA: Eaton Publishing, 2000, 33 pages.
[cited by applicant]
Taylor et al.: Impact of surface chemistry and blocking strategies on DNA microarrays. Nucleic Acids Research, 31(16):e87 19 pages (2003).
[cited by applicant]
Tian et al.: Accurate multiplex gene synthesis from programmable DNA microchips. Nature. 432(7020):1050-1054 (2004).
[cited by applicant]
U.S. Appl. No. 14/452,429 Notice of Allowance dated Jun. 7, 2016.
[cited by applicant]
U.S. Appl. No. 14/452,429 Office Action mailed Apr. 9, 2015.
[cited by applicant]
U.S. Appl. No. 14/452,429 Office Action mailed Oct. 21, 2015.
[cited by applicant]
U.S. Appl. No. 14/452,429 Restriction Requirement mailed Dec. 12, 2014.
[cited by applicant]
U.S. Appl. No. 14/885,962 Notice of Allowance dated Nov. 8, 2017 and Sep. 29, 2017.
[cited by applicant]
U.S. Appl. No. 14/885,962 Office Action dated Dec. 16, 2016.
[cited by applicant]
U.S. Appl. No. 14/885,962 Office Action dated Sep. 8, 2016.
[cited by applicant]
U.S. Appl. No. 14/885,962 Restriction Requirement dated Mar. 1, 2016.
[cited by applicant]
U.S. Appl. No. 14/885,963 Notice of Allowance dated May 24, 2016.
[cited by applicant]
U.S. Appl. No. 14/885,963 Office Action dated Feb. 5, 2016.
[cited by applicant]
U.S. Appl. No. 14/885,965 Office Action dated Aug. 28, 2018.
[cited by applicant]
U.S. Appl. No. 14/885,965 Office Action dated Aug. 30, 2017.
[cited by applicant]
U.S. Appl. No. 14/885,965 Office Action dated Feb. 10, 2017.
[cited by applicant]
U.S. Appl. No. 14/885,965 Office Action dated Feb. 18, 2016.
[cited by applicant]
U.S. Appl. No. 14/885,965 Office Action dated Jan. 4, 2018.
[cited by applicant]
U.S. Appl. No. 14/885,965 Office Action dated Jul. 7, 2016.
[cited by applicant]
U.S. Appl. No. 15/187,714 Final Office Action dated Sep. 17, 2019.
[cited by applicant]
U.S. Appl. No. 15/187,714 Office Action dated Apr. 4, 2019.
[cited by applicant]
U.S. Appl. No. 15/187,714 Restriction Requirement dated Sep. 17, 2018.
[cited by applicant]
U.S. Appl. No. 15/187,721 Notice of Allowance dated Dec. 7, 2016.
[cited by applicant]
U.S. Appl. No. 15/187,721 Office Action dated Oct. 14, 2016.
[cited by applicant]
U.S. Appl. No. 15/233,835 Notice of Allowance dated Oct. 4, 2017.
[cited by applicant]
U.S. Appl. No. 15/233,835 Office Action dated Feb. 8, 2017.
[cited by applicant]
U.S. Appl. No. 15/233,835 Office Action dated Jul. 26, 2017.
[cited by applicant]
U.S. Appl. No. 15/233,835 Restriction Requirement dated Nov. 4, 2016.
[cited by applicant]
U.S. Appl. No. 15/245,054 Notice of Allowance dated Dec. 14, 2017.
[cited by applicant]
U.S. Appl. No. 15/245,054 Office Action dated Mar. 21, 2017.
[cited by applicant]
U.S. Appl. No. 15/245,054 Office Action dated Oct. 19, 2016.
[cited by applicant]
U.S. Appl. No. 15/377,547 Final Office Action dated Feb. 8, 2019.
[cited by applicant]
U.S. Appl. No. 15/377,547 Office Action dated Jul. 27, 2018.
[cited by applicant]
U.S. Appl. No. 15/377,547 Office Action dated Mar. 24, 2017.
[cited by applicant]
U.S. Appl. No. 15/377,547 Office Action dated Nov. 30, 2017.
[cited by applicant]
U.S. Appl. No. 15/602,991 Final Office Action dated Dec. 13, 2018.
[cited by applicant]
U.S. Appl. No. 15/602,991 Notice of Allowance dated Oct. 25, 2017.
[cited by applicant]
U.S. Appl. No. 15/602,991 Office Action dated May 31, 2018.
[cited by applicant]
U.S. Appl. No. 15/602,991 Office Action dated May 31, 2019.
[cited by applicant]
U.S. Appl. No. 15/602,991 Office Action dated Sep. 21, 2017.
[cited by applicant]
U.S. Appl. No. 15/603,013 Final Office Action dated Nov. 6, 2019.
[cited by applicant]
U.S. Appl. No. 15/603,013 Office Action dated Jan. 30, 2018.
[cited by applicant]
U.S. Appl. No. 15/603,013 Office Action dated Jul. 10, 2018.
[cited by applicant]
U.S. Appl. No. 15/603,013 Office Action dated Jun. 26, 2019.
[cited by applicant]
U.S. Appl. No. 15/603,013 Office Action dated Oct. 20, 2017.
[cited by applicant]
U.S. Appl. No. 15/729,564 Final Office Action dated Dec. 13, 2018.
[cited by applicant]
U.S. Appl. No. 15/729,564 Office Action dated Jan. 8, 2018.
[cited by applicant]
U.S. Appl. No. 15/729,564 Office Action dated Jun. 6, 2018.
[cited by applicant]
U.S. Appl. No. 15/729,564 Office Action dated May 30, 2019.
[cited by applicant]
U.S. Appl. No. 15/991,992 Office Action dated May 21, 2020.
[cited by applicant]
U.S. Appl. No. 15/991,992 Restriction Requirement dated Mar. 10, 2020.
[cited by applicant]
U.S. Appl. No. 16/039,256 Final Office Action dated Mar. 30, 2021.
[cited by applicant]
U.S. Appl. No. 16/039,256 Office Action dated Aug. 20, 2020.
[cited by applicant]
U.S. Appl. No. 16/039,256 Office Action dated May 10, 2022.
[cited by applicant]
U.S. Appl. No. 16/039,256 Restriction Requirement dated May 18, 2020.
[cited by applicant]
U.S. Appl. No. 16/409,608 Office Action dated Sep. 9, 2019.
[cited by applicant]
U.S. Appl. No. 16/535,777 Final Office Action dated Oct. 20, 2020.
[cited by applicant]
U.S. Appl. No. 16/535,777 Office Action dated Feb. 8, 2021.
[cited by applicant]
U.S. Appl. No. 16/535,777 Office Action dated Jan. 23, 2020.
[cited by applicant]
U.S. Appl. No. 16/535,779 First Action Interview dated Feb. 10, 2020.
[cited by applicant]
U.S. Appl. No. 16/737,401 Final Office Action dated Jun. 13, 2022.
[cited by applicant]
U.S. Appl. No. 16/737,401 Office Action dated Jan. 5, 2022.
[cited by applicant]
U.S. Appl. No. 16/737,401 Restriction Requirement dated Nov. 15, 2021.
[cited by applicant]
Van Tassell et al.: SNP discovery and allele frequency estimation by deep sequencing of reduced representation libraries. Nature Methods. 5:247-252 (2008).
[cited by applicant]
Xu et al.: Design of 240,000 orthogonal 25mer DNA barcode probes. PNAS. 106(7):2289-2294 (2009).
[cited by applicant]
Yuan et al.: Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. MABS 14(1):e2002236 1-17 (2022).
[cited by applicant]